

Supplementary table 1: Characteristics of included patients: (i) axSpA with psoriasis stratified into HLA-B27 positive vs. negative , (ii) PsA fulfilling clinical definition of axial manifestation stratified into HLA-B27 positive vs. negative, (iii) PsA fulfilling imaging definition stratified into HLA-B27 positive vs. negative.

	axSpA with psoriasis		axPsA positive clinical definition		axPsA positive imaging definition	
	HLA+	HLA-	HLA+	HLA-	HLA+	HLA-
n	111	54	48	165	35	109
Female gender, n (%)	36 (32)	31 (57)	27 (56)	99 (60)	19 (54)	64 (59)
Age, mean (SD)	46.1 (12.8)	46.4 (12.4)	46 (11.9)	52 (10.9)	48.3 (11.9)	52.8 (11.1)
Symptom duration, mean (SD)	17.2 (12.5)	9.4 (9.1)	13.3 (12.7)	10 (9.8)	13.5 (12.6)	10.3 (9)
Disease duration, mean (SD)	9.6 (10.9)	3.5 (4)	8.4 (7.9)	6.4 (8.2)	8.8 (8.2)	6.1 (6.9)
CRP mg/l, mean (SD)	10.3 (15.8)	12.1 (18.2)	12.2 (20.5)	7.3 (9.6)	9 (20)	6 (6.5)
CRP >=5 mg/L, n (%)	45 (45)	21 (42)	21 (50)	55 (35)	11 (35)	40 (40)
BMI, mean (SD)	28.3 (5.4)	28.3 (6)	27.9 (5.7)	29 (6.5)	27.7 (5.8)	28.5 (6.2)
Obesity (BMI>=30), n (%)	35 (34)	20 (38)	13 (27)	61 (37)	9 (26)	36 (34)
peripheral manifestations, n (%)	31 (28)	26 (48)	35 (73)	143 (87)	28 (80)	100 (92)
Uveitis, ever, n (%)	22 (20)	4 (7)	8 (17)	1 (1)	6 (17)	1 (1)
IBD, ever, n (%)	7 (6)	6 (11)	3 (6)	8 (5)	2 (6)	5 (5)
physician global disease activity (NRS), mean (SD)	5.9 (2.2)	5.3 (2)	5.5 (1.8)	5.5 (1.9)	5.4 (1.9)	5.4 (1.9)
patient global disease activity (NRS), mean (SD)	5.7 (2.4)	5.7 (2.7)	6 (2.3)	5.9 (2.4)	5.8 (2)	5.9 (2.3)
patient pain (NRS), mean (SD)	5.7 (2.4)	5.8 (2.5)	5.5 (2.7)	5.8 (2.3)	5.5 (2.6)	5.7 (2.2)
Sleep disorder (NRS), mean (SD)	5.7 (3)	5.8 (2.7)	5.2 (3.4)	5.7 (3)	4.5 (3.7)	5.8 (2.9)